| # | Country | Total Patents | |
|---|---|---|---|
| #1 | WIPO (World Intellectual Property Organization) | 3 | |
| #2 | Canada | 2 | |
| #3 | China | 2 | |
| #4 | Australia | 1 | |
| #5 | Brazil | 1 | |
| #6 | EPO (European Patent Office) | 1 | |
| #7 | Israel | 1 | |
| #8 | United States | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Peptides | |
| #3 | Medical preparations | |
| #4 | Microorganisms |
| # | Name | Total Patents |
|---|---|---|
| #1 | Holers V Michael | 7 |
| #2 | Flynn Peter | 5 |
| #3 | Emlen Woodruff | 4 |
| #4 | Risitano Antonio M | 3 |
| #5 | Holers Michael V | 2 |
| #6 | Holers V | 1 |
| #7 | Kovacs James | 1 |
| #8 | Michael Risitano Antonio M | 1 |
| #9 | Hannan Jonathan P | 1 |
| #10 | Michael Holers V | 1 |
| Publication | Filing date | Title |
|---|---|---|
| AU2010314931A1 | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis | |
| WO2010033868A2 | Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof |